

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.2	117.3	(70.6-183.2)	Male	10	11.4	87.6	(41.9-161.1)
Female	6	6.0	100.7	(36.8-219.2)	Female	12	9.1	132.5	(68.4-231.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.4	177.7	(64.9-386.7)	Male	1	2.8	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	9.8	133.3	(70.9-227.9)
Female	66	65.2	101.2	(78.3-128.8)	Female	12	7.8	153.2	(79.1-267.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	8	7.2	110.6	(47.6-217.9)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	25	20.5	122.0	(79.0-180.2)	<u>Ovary</u>				
Female	21	19.2	109.2	(67.5-166.9)	Female	10	6.2	161.0	(77.1-296.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.6	109.2	(35.2-254.9)	Male	1	5.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	7	5.5	126.3	(50.6-260.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.5	nc	(nc-nc)	Male	55	69.1	79.6	(60.0-103.6)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.9	nc	(nc-nc)
Male	14	9.6	146.4	(80.0-245.7)	Female	0	2.2	nc	(nc-nc)
Female	10	5.3	187.1	(89.6-344.2)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.8	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	17	12.2	139.2	(81.1-222.9)
Male	5	6.2	80.8	(26.0-188.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.5	nc	(nc-nc)	Female	13	15.1	86.3	(45.9-147.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.1	nc	(nc-nc)	Male	230	234.0	98.3	(86.0-111.9)
Female	2	1.6	nc	(nc-nc)	Female	251	222.3	112.9	(99.4-127.8)
<u>Lung and Bronchus</u>									
Male	37	30.8	120.3	(84.7-165.8)					
Female	40	31.4	127.3	(90.9-173.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	17.8	78.6	(42.9-131.8)	Male	21	12.9	162.2	(100.4-248.0)
Female	7	5.8	121.7	(48.7-250.7)	Female	13	10.2	127.6	(67.9-218.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.1	123.2	(39.7-287.6)	Male	2	3.1	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	5	2.2	232.1	(74.8-541.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	11.3	79.6	(36.3-151.1)
Female	96	74.0	129.8	(105.1-158.5)	Female	8	8.1	99.1	(42.7-195.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.4	nc	(nc-nc)
Male	22	23.0	95.7	(59.9-144.8)	<u>Ovary</u>				
Female	15	19.8	75.7	(42.3-124.8)	Female	12	6.8	176.8	(91.3-308.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.1	nc	(nc-nc)	Male	10	5.9	168.7	(80.8-310.3)
Female	0	1.2	nc	(nc-nc)	Female	7	5.4	129.7	(52.0-267.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	75	73.8	101.7	(80.0-127.5)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.3	nc	(nc-nc)
Male	14	11.0	127.1	(69.4-213.3)	Female	4	2.2	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.9	208.5	(76.1-453.9)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	5	4.7	106.3	(34.3-248.1)
<u>Leukemia</u>					Female	12	14.9	80.7	(41.6-140.9)
Male	7	7.1	98.0	(39.3-202.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	4.8	188.3	(85.9-357.5)	Female	19	16.5	115.2	(69.3-179.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.9	nc	(nc-nc)	Male	231	259.3	89.1	(78.0-101.3)
Female	0	1.7	nc	(nc-nc)	Female	252	238.3	105.7	(93.1-119.6)
<u>Lung and Bronchus</u>									
Male	14	33.7	41.6	(22.7-69.8)					
Female	17	30.0	56.6	(32.9-90.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.3	89.4	(44.5-159.9)	Male	6	8.0	74.9	(27.4-163.1)
Female	5	4.2	119.9	(38.7-279.9)	Female	4	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.9	101.2	(40.5-208.5)
Female	50	41.8	119.7	(88.9-157.8)	Female	3	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	5	4.9	101.9	(32.8-237.9)
<u>Colon / Rectum</u>					Female	2	2.1	nc	(nc-nc)
Male	21	14.8	141.7	(87.7-216.7)	<u>Ovary</u>				
Female	19	13.6	140.2	(84.3-218.9)	Female	4	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	74	47.9	154.4	(121.2-193.8)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.9	nc	(nc-nc)
Male	7	6.6	105.6	(42.3-217.5)	Female	0	1.6	nc	(nc-nc)
Female	5	3.5	141.3	(45.5-329.8)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	5	1.9	260.7	(84.0-608.5)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	110.2	(47.5-217.2)
Male	5	4.5	111.9	(36.1-261.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.1	nc	(nc-nc)	Female	5	9.8	51.3	(16.5-119.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.5	nc	(nc-nc)	Male	201	166.3	120.9	(104.7-138.8)
Female	0	1.1	nc	(nc-nc)	Female	147	147.2	99.9	(84.4-117.4)
<u>Lung and Bronchus</u>									
Male	27	22.5	119.8	(78.9-174.3)					
Female	19	21.4	88.8	(53.4-138.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.2	128.1	(68.1-219.0)	Male	8	6.5	123.8	(53.3-243.9)
Female	6	4.2	141.6	(51.7-308.3)	Female	1	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.6	142.5	(61.3-280.8)
Female	33	40.1	82.4	(56.7-115.7)	Female	6	5.3	112.6	(41.1-245.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	23	12.2	189.3	(120.0-284.0)	<u>Ovary</u>				
Female	17	14.0	121.7	(70.8-194.8)	Female	6	3.9	152.3	(55.6-331.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	7	3.3	213.4	(85.5-439.7)
Female	1	0.9	nc	(nc-nc)	Female	7	4.0	173.4	(69.5-357.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	65	39.9	162.8	(125.6-207.5)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	6	5.3	112.2	(41.0-244.3)	Female	3	1.6	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	6.5	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.0	nc	(nc-nc)	Female	9	9.2	98.0	(44.7-186.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	176	136.6	128.8	(110.5-149.3)
Female	0	1.1	nc	(nc-nc)	Female	145	144.1	100.6	(84.9-118.4)
<u>Lung and Bronchus</u>									
Male	19	18.8	100.9	(60.7-157.5)					
Female	38	21.5	176.6	(124.9-242.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	37.4	85.6	(58.6-120.9)	Male	20	23.4	85.3	(52.1-131.8)
Female	15	14.0	107.1	(59.9-176.7)	Female	13	18.1	72.0	(38.3-123.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.5	138.2	(63.1-262.4)	Male	3	6.0	nc	(nc-nc)
Female	8	5.6	142.8	(61.5-281.4)	Female	4	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	14	20.7	67.8	(37.0-113.7)
Female	154	131.8	116.9	(99.2-136.9)	Female	19	17.3	109.6	(65.9-171.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.7	105.4	(34.0-246.0)	Male	16	14.1	113.1	(64.6-183.7)
<u>Colon / Rectum</u>					Female	6	6.8	88.7	(32.4-193.0)
Male	49	44.7	109.7	(81.2-145.1)	<u>Ovary</u>				
Female	55	47.0	116.9	(88.1-152.2)	Female	15	13.1	114.7	(64.2-189.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	9.3	107.1	(51.3-197.0)	Male	11	11.9	92.5	(46.1-165.6)
Female	5	2.8	177.8	(57.3-415.0)	Female	13	13.5	96.5	(51.3-165.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.7	nc	(nc-nc)	Male	126	131.8	95.6	(79.6-113.8)
Female	6	2.2	274.8	(100.4-598.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	8.6	185.9	(106.2-301.9)
Male	17	19.0	89.4	(52.1-143.2)	Female	3	5.6	nc	(nc-nc)
Female	15	11.1	135.0	(75.5-222.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.1	nc	(nc-nc)
Male	4	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	7	7.2	97.7	(39.1-201.3)
<u>Leukemia</u>					Female	20	21.3	93.8	(57.3-144.9)
Male	7	13.3	52.5	(21.0-108.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	10.1	79.2	(34.1-156.0)	Female	24	30.1	79.7	(51.1-118.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	10.1	69.1	(27.7-142.4)	Male	451	481.6	93.6	(85.2-102.7)
Female	3	3.6	nc	(nc-nc)	Female	495	472.8	104.7	(95.7-114.3)
<u>Lung and Bronchus</u>									
Male	56	66.1	84.8	(64.0-110.1)					
Female	69	67.7	101.9	(79.3-129.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	5	4.0	125.8	(40.5-293.6)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	13.5	74.2	(35.5-136.4)
Female	0	0.1	nc	(nc-nc)	Female	6	11.3	53.1	(19.4-115.5)
<u>Lung and Bronchus</u>									
Male	0	2.0	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.0	128.2	(76.0-202.7)	Male	18	10.2	176.6	(104.6-279.1)
Female	6	6.4	93.2	(34.0-202.8)	Female	14	9.7	144.6	(79.0-242.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.1	160.1	(51.6-373.5)	Male	4	2.4	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	16	8.8	181.5	(103.7-294.8)
Female	70	69.9	100.2	(78.1-126.5)	Female	15	8.4	177.7	(99.4-293.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	15	6.6	228.3	(127.7-376.6)
<u>Colon / Rectum</u>					Female	7	3.4	205.7	(82.4-423.8)
Male	20	18.1	110.3	(67.3-170.3)	<u>Ovary</u>				
Female	26	21.9	118.5	(77.4-173.7)	Female	5	6.7	75.0	(24.2-175.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.0	174.9	(70.1-360.4)	Male	5	4.7	106.9	(34.4-249.4)
Female	1	1.3	nc	(nc-nc)	Female	2	6.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	45	59.3	75.9	(55.4-101.6)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	3.4	nc	(nc-nc)
Male	3	8.6	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	12.6	47.4	(17.3-103.3)
Male	8	5.5	144.3	(62.1-284.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.9	nc	(nc-nc)	Female	16	15.8	101.1	(57.8-164.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.6	130.7	(47.7-284.6)	Male	229	205.6	111.4	(97.4-126.8)
Female	2	1.8	nc	(nc-nc)	Female	244	238.7	102.2	(89.8-115.9)
<u>Lung and Bronchus</u>									
Male	37	26.6	138.9	(97.8-191.5)					
Female	36	32.5	110.8	(77.6-153.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.2	73.1	(39.9-122.6)	Male	8	13.8	58.1	(25.0-114.4)
Female	7	7.0	100.6	(40.3-207.2)	Female	8	12.6	63.5	(27.3-125.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	4.6	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	12.7	86.8	(43.2-155.2)
Female	90	72.3	124.5	(100.1-153.0)	Female	10	9.8	101.6	(48.7-186.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	8	8.5	93.8	(40.4-184.8)
<u>Colon / Rectum</u>					Female	3	3.8	nc	(nc-nc)
Male	17	23.6	72.0	(41.9-115.3)	<u>Ovary</u>				
Female	17	23.0	74.0	(43.1-118.4)	Female	10	7.7	129.7	(62.1-238.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.3	nc	(nc-nc)	Male	6	6.2	96.5	(35.2-210.0)
Female	0	1.4	nc	(nc-nc)	Female	5	6.5	76.8	(24.7-179.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	4.0	nc	(nc-nc)	Male	81	78.9	102.6	(81.5-127.5)
Female	1	3.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.5	nc	(nc-nc)
Male	9	10.8	83.2	(38.0-158.0)	Female	2	2.6	nc	(nc-nc)
Female	6	6.1	98.5	(36.0-214.5)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.5	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
<u>Leukemia</u>					Female	11	17.0	64.7	(32.2-115.8)
Male	6	8.4	71.6	(26.2-155.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.9	nc	(nc-nc)	Female	10	17.2	58.2	(27.9-107.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.8	nc	(nc-nc)	Male	214	282.3	75.8	(66.0-86.7)
Female	2	1.9	nc	(nc-nc)	Female	229	265.1	86.4	(75.5-98.3)
<u>Lung and Bronchus</u>									
Male	15	35.5	42.2	(23.6-69.7)					
Female	20	35.1	57.0	(34.8-88.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	35.3	99.0	(69.0-137.7)	Male	23	23.9	96.3	(61.0-144.5)
Female	13	13.4	97.2	(51.7-166.3)	Female	20	19.1	104.8	(64.0-161.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.0	99.9	(40.0-205.8)	Male	8	6.0	133.8	(57.6-263.6)
Female	5	6.0	83.9	(27.0-195.8)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	22	20.7	106.4	(66.6-161.0)
Female	127	141.6	89.7	(74.8-106.7)	Female	20	17.3	115.8	(70.7-178.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.2	nc	(nc-nc)	Male	19	15.1	125.5	(75.5-195.9)
<u>Colon / Rectum</u>					Female	3	6.9	nc	(nc-nc)
Male	35	43.4	80.7	(56.2-112.2)	<u>Ovary</u>				
Female	35	44.6	78.4	(54.6-109.1)	Female	19	13.5	141.0	(84.8-220.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.7	113.0	(56.3-202.2)	Male	12	11.6	103.2	(53.3-180.2)
Female	3	2.7	nc	(nc-nc)	Female	12	12.7	94.5	(48.8-165.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.9	nc	(nc-nc)	Male	164	143.6	114.2	(97.4-133.1)
Female	1	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	8.3	144.0	(74.3-251.6)
Male	14	20.1	69.6	(38.0-116.8)	Female	4	5.1	nc	(nc-nc)
Female	11	11.6	95.2	(47.4-170.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.4	113.3	(36.5-264.3)
Male	5	5.7	87.8	(28.3-205.0)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	11	7.9	138.9	(69.3-248.6)
<u>Leukemia</u>					Female	34	24.2	140.3	(97.1-196.0)
Male	15	13.1	114.3	(63.9-188.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.0	109.5	(54.6-195.9)	Female	35	32.0	109.3	(76.1-152.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.8	92.4	(44.2-169.9)	Male	474	493.3	96.1	(87.6-105.1)
Female	1	3.6	nc	(nc-nc)	Female	442	485.0	91.1	(82.8-100.0)
<u>Lung and Bronchus</u>									
Male	28	66.5	42.1	(28.0-60.8)					
Female	46	68.2	67.5	(49.4-90.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	6.0	100.0	(36.5-217.6)
Female	0	0.1	nc	(nc-nc)	Female	5	6.9	72.4	(23.3-168.9)
<u>Lung and Bronchus</u>									
Male	0	0.8	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	45.0	113.2	(84.3-148.9)	Male	38	29.8	127.3	(90.1-174.8)
Female	18	19.5	92.3	(54.7-145.8)	Female	37	26.9	137.3	(96.7-189.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.6	104.4	(47.6-198.2)	Male	8	7.5	106.8	(46.0-210.5)
Female	5	8.2	60.7	(19.6-141.7)	Female	11	7.0	157.0	(78.3-281.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	29	25.8	112.6	(75.4-161.7)
Female	218	194.4	112.2	(97.8-128.1)	Female	29	24.8	117.0	(78.3-168.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	7.4	nc	(nc-nc)	Male	13	18.0	72.1	(38.4-123.4)
<u>Colon / Rectum</u>					Female	17	9.7	175.4	(102.1-280.8)
Male	55	55.1	99.9	(75.3-130.0)	<u>Ovary</u>				
Female	75	64.8	115.8	(91.1-145.1)	Female	23	18.6	123.7	(78.4-185.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	11.8	126.9	(71.0-209.3)	Male	14	14.6	96.2	(52.5-161.4)
Female	4	4.1	nc	(nc-nc)	Female	24	18.6	129.0	(82.6-191.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.7	nc	(nc-nc)	Male	142	171.6	82.7	(69.7-97.5)
Female	5	3.3	153.8	(49.6-358.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	10.5	85.6	(39.0-162.4)
Male	24	24.5	98.1	(62.8-145.9)	Female	5	7.5	67.0	(21.6-156.4)
Female	16	16.4	97.6	(55.7-158.4)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.3	127.9	(55.1-252.1)
Male	1	6.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	2.3	nc	(nc-nc)	Male	10	9.8	102.2	(48.9-188.0)
<u>Leukemia</u>					Female	32	33.9	94.4	(64.5-133.2)
Male	17	16.4	103.4	(60.2-165.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	14.2	119.7	(69.7-191.6)	Female	41	43.1	95.0	(68.2-128.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	13.1	84.1	(41.9-150.6)	Male	581	609.3	95.4	(87.8-103.4)
Female	5	5.2	95.7	(30.8-223.4)	Female	735	684.3	107.4	(99.8-115.5)
<u>Lung and Bronchus</u>									
Male	74	83.0	89.1	(70.0-111.9)					
Female	83	99.2	83.7	(66.6-103.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.8	124.7	(45.5-271.5)	Male	1	3.8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	19	21.5	88.3	(53.2-137.9)	Female	4	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	5	6.4	77.9	(25.1-181.9)	<u>Ovary</u>				
Female	6	5.2	114.3	(41.7-248.8)	Female	0	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.6	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	22	24.5	89.8	(56.2-135.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.9	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.4	135.5	(49.5-294.9)
Male	2	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	7	4.9	141.9	(56.8-292.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	66	77.8	84.8	(65.6-107.9)
Female	0	0.5	nc	(nc-nc)	Female	75	68.1	110.1	(86.6-138.0)
<u>Lung and Bronchus</u>									
Male	4	9.6	nc	(nc-nc)					
Female	11	8.7	126.0	(62.8-225.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	9	11.4	79.1	(36.1-150.2)	Female	6	1.3	474.6	(173.3-1032.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	10.6	85.2	(38.9-161.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	5	2.6	195.9	(63.1-457.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	37.4	80.2	(54.1-114.5)
Female	0	0.3	nc	(nc-nc)	Female	41	37.1	110.4	(79.2-149.8)
<u>Lung and Bronchus</u>									
Male	4	4.9	nc	(nc-nc)					
Female	2	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	13	8.2	158.6	(84.4-271.3)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	1.9	269.9	(87.0-630.0)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	6.5	154.2	(73.8-283.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	5	2.0	251.0	(80.9-585.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	27	21.5	125.4	(82.6-182.5)
Female	0	0.2	nc	(nc-nc)	Female	28	25.9	108.1	(71.8-156.3)
<u>Lung and Bronchus</u>									
Male	3	2.7	nc	(nc-nc)					
Female	0	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.4	111.9	(62.6-184.5)	Male	10	9.8	102.4	(49.0-188.3)
Female	4	4.6	nc	(nc-nc)	Female	7	8.1	86.5	(34.6-178.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	6	2.3	256.0	(93.5-557.2)
Female	5	2.5	202.3	(65.2-472.2)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	8.4	82.9	(33.2-170.8)
Female	79	58.9	134.1	(106.1-167.1)	Female	9	6.5	139.1	(63.5-264.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	7	6.3	111.5	(44.7-229.7)
<u>Colon / Rectum</u>					Female	0	2.7	nc	(nc-nc)
Male	11	17.1	64.5	(32.1-115.4)	<u>Ovary</u>				
Female	20	15.4	130.1	(79.4-200.9)	Female	15	5.4	276.5	(154.6-456.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	3.8	nc	(nc-nc)	Male	7	4.5	156.8	(62.8-323.0)
Female	0	0.9	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	69	54.9	125.7	(97.8-159.1)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.2	nc	(nc-nc)
Male	11	8.2	133.8	(66.7-239.5)	Female	3	1.7	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	7	3.6	197.2	(79.0-406.2)
<u>Leukemia</u>					Female	19	11.6	164.3	(98.9-256.6)
Male	5	5.3	94.2	(30.4-219.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.8	nc	(nc-nc)	Female	13	13.7	95.2	(50.6-162.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.4	nc	(nc-nc)	Male	202	194.0	104.1	(90.2-119.5)
Female	4	1.4	nc	(nc-nc)	Female	240	191.2	125.5	(110.2-142.5)
<u>Lung and Bronchus</u>									
Male	20	25.2	79.3	(48.4-122.5)					
Female	28	25.6	109.5	(72.8-158.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.3	132.9	(80.0-207.6)	Male	7	8.9	78.5	(31.4-161.7)
Female	7	5.6	124.2	(49.8-255.9)	Female	7	7.3	95.8	(38.4-197.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.8	114.9	(52.4-218.1)
Female	34	51.8	65.7	(45.5-91.8)	Female	5	7.0	71.0	(22.9-165.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	9	5.3	169.7	(77.4-322.1)
<u>Colon / Rectum</u>					Female	2	2.7	nc	(nc-nc)
Male	19	17.0	111.9	(67.4-174.8)	<u>Ovary</u>				
Female	21	19.3	108.8	(67.3-166.4)	Female	10	5.1	194.3	(93.0-357.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	169.1	(61.8-368.1)	Male	5	4.6	109.5	(35.3-255.6)
Female	1	1.2	nc	(nc-nc)	Female	6	5.5	109.7	(40.1-238.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.1	nc	(nc-nc)	Male	49	50.4	97.3	(71.9-128.6)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.3	nc	(nc-nc)
Male	6	7.2	83.7	(30.6-182.2)	Female	1	2.3	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	8.6	58.2	(18.7-135.7)
Male	5	5.2	96.5	(31.1-225.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.1	169.5	(67.9-349.3)	Female	14	11.6	120.7	(66.0-202.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.8	nc	(nc-nc)	Male	189	184.1	102.7	(88.6-118.4)
Female	1	1.5	nc	(nc-nc)	Female	165	189.0	87.3	(74.5-101.7)
<u>Lung and Bronchus</u>									
Male	32	25.3	126.5	(86.5-178.6)					
Female	29	27.0	107.2	(71.8-154.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	40.3	139.1	(105.1-180.6)	Male	28	28.2	99.2	(65.9-143.4)
Female	12	15.9	75.5	(39.0-131.9)	Female	24	23.5	102.2	(65.5-152.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	8.7	173.4	(97.0-286.0)	Male	3	6.8	nc	(nc-nc)
Female	6	7.4	80.7	(29.5-175.7)	Female	7	5.7	122.5	(49.1-252.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	20	24.5	81.5	(49.7-125.8)
Female	173	164.7	105.0	(90.0-121.9)	Female	18	20.6	87.2	(51.7-137.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.7	nc	(nc-nc)	Male	27	17.5	154.3	(101.7-224.5)
<u>Colon / Rectum</u>					Female	4	8.2	nc	(nc-nc)
Male	50	50.0	100.0	(74.2-131.8)	<u>Ovary</u>				
Female	42	52.7	79.8	(57.5-107.8)	Female	21	15.8	132.7	(82.1-202.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	11.0	63.8	(25.6-131.5)	Male	10	13.1	76.1	(36.4-140.0)
Female	3	3.3	nc	(nc-nc)	Female	13	15.1	86.2	(45.9-147.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	4.1	170.4	(68.3-351.1)	Male	140	157.5	88.9	(74.8-104.9)
Female	1	3.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.5	104.9	(50.2-192.9)
Male	27	23.5	115.1	(75.8-167.5)	Female	6	6.1	98.8	(36.1-214.9)
Female	14	13.8	101.3	(55.3-170.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	7.1	70.0	(22.6-163.4)
Male	7	6.4	109.1	(43.7-224.8)	<u>Thyroid</u>				
Female	3	1.9	nc	(nc-nc)	Male	10	10.0	99.6	(47.7-183.2)
<u>Leukemia</u>					Female	25	31.2	80.2	(51.9-118.4)
Male	13	15.3	85.1	(45.3-145.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	12.2	106.6	(56.7-182.3)	Female	30	37.0	81.0	(54.7-115.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	12.6	127.3	(72.7-206.8)	Male	579	564.7	102.5	(94.4-111.2)
Female	7	4.3	161.4	(64.7-332.5)	Female	555	576.6	96.3	(88.4-104.6)
<u>Lung and Bronchus</u>									
Male	100	75.4	132.6	(107.9-161.2)					
Female	94	81.2	115.8	(93.6-141.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	20.5	87.9	(52.1-138.9)	Male	8	13.0	61.7	(26.6-121.6)
Female	10	7.5	132.7	(63.5-244.0)	Female	10	10.3	97.2	(46.5-178.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.6	164.8	(60.2-358.7)	Male	3	3.3	nc	(nc-nc)
Female	6	3.2	187.0	(68.3-407.1)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	11.3	61.8	(24.8-127.4)
Female	58	74.8	77.5	(58.9-100.2)	Female	10	9.6	104.2	(49.9-191.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	10	7.7	129.7	(62.1-238.6)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	30	24.2	123.9	(83.6-176.9)	<u>Ovary</u>				
Female	25	24.9	100.4	(65.0-148.2)	Female	12	7.2	165.7	(85.5-289.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.2	115.3	(42.1-250.9)	Male	7	6.6	106.7	(42.7-219.8)
Female	3	1.6	nc	(nc-nc)	Female	11	7.2	153.4	(76.5-274.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	71	74.5	95.3	(74.4-120.2)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.7	149.8	(60.0-308.7)
Male	13	10.6	123.2	(65.5-210.7)	Female	2	2.8	nc	(nc-nc)
Female	4	6.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.4	207.4	(66.8-484.1)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	18	12.6	143.1	(84.8-226.2)
Male	7	7.2	97.0	(38.9-199.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	5.5	nc	(nc-nc)	Female	17	17.0	99.8	(58.1-159.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.6	106.2	(38.8-231.2)	Male	270	267.4	101.0	(89.3-113.8)
Female	0	2.0	nc	(nc-nc)	Female	266	264.2	100.7	(89.0-113.6)
<u>Lung and Bronchus</u>									
Male	39	37.3	104.4	(74.2-142.8)					
Female	52	38.9	133.7	(99.9-175.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.6	142.6	(61.4-281.0)	Male	3	3.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	18	21.4	84.0	(49.8-132.8)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	7	6.8	103.2	(41.4-212.7)	<u>Ovary</u>				
Female	4	6.7	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	21.2	47.1	(22.5-86.6)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	5	2.9	169.8	(54.7-396.2)	Female	1	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.5	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	6	5.2	116.5	(42.5-253.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	75	74.7	100.4	(79.0-125.9)
Female	2	0.6	nc	(nc-nc)	Female	71	74.9	94.8	(74.1-119.6)
<u>Lung and Bronchus</u>									
Male	10	10.2	98.4	(47.1-180.9)					
Female	15	11.5	130.7	(73.1-215.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.0	nc	(nc-nc)	Male	5	5.2	96.2	(31.0-224.5)
Female	2	3.2	nc	(nc-nc)	Female	5	4.2	117.7	(37.9-274.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	27	29.8	90.5	(59.6-131.7)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	5	8.9	56.3	(18.2-131.4)	<u>Ovary</u>				
Female	13	10.6	122.9	(65.4-210.2)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	27	28.5	94.7	(62.4-137.7)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	0	4.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.3	94.2	(30.4-219.9)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.3	nc	(nc-nc)	Female	10	6.4	157.0	(75.2-288.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	84	101.6	82.7	(65.9-102.4)
Female	0	0.8	nc	(nc-nc)	Female	103	107.1	96.1	(78.5-116.6)
<u>Lung and Bronchus</u>									
Male	20	13.1	152.2	(92.9-235.1)					
Female	10	15.2	65.7	(31.5-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	89	70.4	126.4	(101.5-155.5)	Male	54	42.8	126.3	(94.8-164.8)
Female	24	25.6	93.7	(60.0-139.4)	Female	43	32.3	133.2	(96.4-179.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	11.4	114.3	(60.8-195.5)	Male	11	11.4	96.7	(48.2-173.0)
Female	14	10.0	139.4	(76.2-234.0)	Female	16	9.2	174.2	(99.5-283.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.0	nc	(nc-nc)	Male	38	37.2	102.1	(72.2-140.1)
Female	257	242.5	106.0	(93.4-119.8)	Female	34	32.0	106.4	(73.6-148.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.2	109.6	(50.0-208.1)	Male	23	25.3	91.0	(57.7-136.6)
<u>Colon / Rectum</u>					Female	17	12.4	137.1	(79.8-219.5)
Male	74	82.1	90.1	(70.8-113.2)	<u>Ovary</u>				
Female	88	82.8	106.3	(85.3-131.0)	Female	25	23.7	105.3	(68.2-155.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	17.6	107.9	(64.9-168.5)	Male	19	22.4	84.7	(50.9-132.2)
Female	1	5.3	nc	(nc-nc)	Female	30	24.3	123.3	(83.2-176.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	4.5	112.3	(36.2-262.1)	Male	333	254.3	130.9	(117.3-145.8)
Female	4	3.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	15.9	94.3	(52.7-155.5)
Male	35	34.6	101.2	(70.5-140.8)	Female	4	9.5	nc	(nc-nc)
Female	16	21.1	75.7	(43.2-122.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.2	96.8	(35.3-210.6)
Male	11	10.1	108.5	(54.1-194.2)	<u>Thyroid</u>				
Female	3	3.0	nc	(nc-nc)	Male	6	12.3	48.8	(17.8-106.2)
<u>Leukemia</u>					Female	18	37.5	48.0	(28.5-75.9)
Male	35	24.1	145.2	(101.1-201.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	17.8	157.4	(104.6-227.5)	Female	54	56.6	95.4	(71.6-124.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	18.8	90.6	(52.8-145.1)	Male	1002	899.9	111.3	(104.6-118.5)
Female	8	6.8	118.1	(50.9-232.7)	Female	912	867.4	105.1	(98.4-112.2)
<u>Lung and Bronchus</u>									
Male	119	127.3	93.5	(77.5-111.9)					
Female	141	132.9	106.1	(89.3-125.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.2	96.3	(35.1-209.5)	Male	1	4.3	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	0	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.3	396.7	(127.9-925.9)	Male	0	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	15	24.3	61.6	(34.5-101.6)	Female	2	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	5	7.8	64.3	(20.7-150.1)	<u>Ovary</u>				
Female	6	8.1	74.2	(27.1-161.5)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	18	27.3	66.0	(39.1-104.4)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.2	nc	(nc-nc)
Male	5	2.3	217.4	(70.1-507.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.7	nc	(nc-nc)	Female	6	5.4	110.8	(40.4-241.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.1	nc	(nc-nc)	Male	73	90.1	81.0	(63.5-101.9)
Female	0	0.7	nc	(nc-nc)	Female	53	84.1	63.0	(47.2-82.5)
<u>Lung and Bronchus</u>									
Male	10	12.0	83.2	(39.8-153.0)					
Female	8	11.4	70.4	(30.3-138.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	10	9.1	109.8	(52.6-202.0)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	10.7	55.8	(20.4-121.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	6	2.2	272.5	(99.5-593.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	26	34.5	75.3	(49.2-110.4)
Female	0	0.2	nc	(nc-nc)	Female	32	30.9	103.4	(70.7-146.0)
<u>Lung and Bronchus</u>									
Male	8	4.7	169.5	(73.0-334.1)					
Female	4	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	22.3	89.7	(54.8-138.6)	Male	20	12.9	154.7	(94.4-238.9)
Female	4	5.9	nc	(nc-nc)	Female	8	7.8	102.5	(44.1-202.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	11.5	95.5	(47.6-170.9)
Female	62	58.8	105.4	(80.8-135.1)	Female	6	7.4	80.8	(29.5-175.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	8	7.3	109.0	(46.9-214.7)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	22	25.6	86.0	(53.9-130.2)	<u>Ovary</u>				
Female	20	19.3	103.6	(63.2-159.9)	Female	5	5.6	88.6	(28.6-206.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.2	nc	(nc-nc)	Male	9	6.9	129.9	(59.3-246.6)
Female	3	1.2	nc	(nc-nc)	Female	5	5.6	89.3	(28.8-208.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	61	72.2	84.5	(64.6-108.5)
Female	3	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.0	140.4	(56.3-289.4)
Male	9	10.3	87.3	(39.8-165.8)	Female	1	2.2	nc	(nc-nc)
Female	5	5.0	100.6	(32.4-234.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	0	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.5	52.9	(17.0-123.3)
Male	8	7.6	104.6	(45.0-206.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.3	nc	(nc-nc)	Female	19	13.4	142.1	(85.5-221.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.5	90.8	(29.3-211.9)	Male	233	270.5	86.1	(75.4-97.9)
Female	0	1.6	nc	(nc-nc)	Female	195	205.6	94.8	(82.0-109.1)
<u>Lung and Bronchus</u>									
Male	26	38.9	66.8	(43.6-97.9)					
Female	28	30.3	92.4	(61.4-133.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.3	89.4	(44.6-160.0)	Male	7	8.9	78.4	(31.4-161.5)
Female	7	4.4	159.6	(64.0-328.9)	Female	8	7.5	106.2	(45.7-209.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.8	102.4	(44.1-201.7)
Female	44	54.3	81.1	(58.9-108.8)	Female	1	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	7	5.9	118.9	(47.6-245.0)
<u>Colon / Rectum</u>					Female	2	2.5	nc	(nc-nc)
Male	19	15.9	119.7	(72.0-186.9)	<u>Ovary</u>				
Female	10	15.3	65.4	(31.3-120.3)	Female	5	4.9	101.4	(32.7-236.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.5	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	57	50.1	113.7	(86.1-147.4)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	7	7.5	93.3	(37.4-192.2)	Female	1	1.7	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	10.7	46.8	(15.1-109.3)
Male	3	4.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.5	nc	(nc-nc)	Female	8	11.7	68.3	(29.4-134.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.1	123.2	(39.7-287.5)	Male	164	177.7	92.3	(78.7-107.6)
Female	0	1.3	nc	(nc-nc)	Female	137	176.9	77.4	(65.0-91.5)
<u>Lung and Bronchus</u>									
Male	18	22.6	79.5	(47.1-125.7)					
Female	24	22.8	105.4	(67.5-156.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.7	95.4	(52.1-160.0)	Male	2	10.3	nc	(nc-nc)
Female	11	5.3	205.9	(102.6-368.4)	Female	12	8.4	142.7	(73.6-249.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.1	191.7	(70.0-417.2)	Male	2	2.5	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	8.9	123.9	(61.8-221.8)
Female	71	59.7	119.0	(93.0-150.1)	Female	9	7.1	126.1	(57.6-239.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.5	203.8	(65.7-475.7)	Male	8	6.4	124.7	(53.7-245.8)
<u>Colon / Rectum</u>					Female	4	2.9	nc	(nc-nc)
Male	22	18.5	118.8	(74.4-179.8)	<u>Ovary</u>				
Female	13	17.8	73.2	(39.0-125.2)	Female	2	5.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.0	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	79	58.6	134.8	(106.7-168.0)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	9	8.5	105.9	(48.3-201.0)	Female	2	2.0	nc	(nc-nc)
Female	8	4.9	164.5	(70.8-324.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.5	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.6	139.0	(44.8-324.4)
<u>Leukemia</u>					Female	10	11.5	86.8	(41.5-159.6)
Male	7	5.7	123.0	(49.3-253.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	4.2	nc	(nc-nc)	Female	15	13.3	112.6	(63.0-185.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.5	nc	(nc-nc)	Male	238	207.1	114.9	(100.8-130.5)
Female	0	1.5	nc	(nc-nc)	Female	232	202.6	114.5	(100.2-130.2)
<u>Lung and Bronchus</u>									
Male	41	27.2	150.8	(108.2-204.6)					
Female	37	28.0	132.4	(93.2-182.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	27.5	83.5	(52.9-125.3)	Male	23	17.7	129.8	(82.3-194.8)
Female	8	11.2	71.7	(30.9-141.3)	Female	19	15.1	126.0	(75.8-196.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.0	119.3	(43.6-259.7)	Male	2	4.5	nc	(nc-nc)
Female	5	4.7	106.3	(34.3-248.1)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	15.4	116.9	(69.3-184.8)
Female	125	110.3	113.3	(94.3-135.0)	Female	9	14.2	63.6	(29.0-120.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	4.1	nc	(nc-nc)	Male	7	10.8	65.0	(26.0-133.9)
<u>Colon / Rectum</u>					Female	4	5.5	nc	(nc-nc)
Male	29	32.8	88.4	(59.2-127.0)	<u>Ovary</u>				
Female	36	36.9	97.5	(68.3-135.0)	Female	17	10.6	160.4	(93.4-256.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	7.2	nc	(nc-nc)	Male	6	8.9	67.5	(24.6-146.9)
Female	0	2.3	nc	(nc-nc)	Female	16	10.7	150.2	(85.8-243.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	114	104.5	109.1	(90.0-131.0)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.4	nc	(nc-nc)
Male	14	14.6	96.2	(52.5-161.4)	Female	3	4.3	nc	(nc-nc)
Female	5	9.3	53.7	(17.3-125.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.2	nc	(nc-nc)
Male	1	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	8	5.6	143.7	(61.9-283.1)
<u>Leukemia</u>					Female	32	18.5	172.6	(118.0-243.6)
Male	4	10.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	8.1	nc	(nc-nc)	Female	22	25.1	87.7	(54.9-132.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.7	nc	(nc-nc)	Male	327	366.8	89.1	(79.7-99.3)
Female	2	3.0	nc	(nc-nc)	Female	384	388.9	98.7	(89.1-109.1)
<u>Lung and Bronchus</u>									
Male	32	50.3	63.6	(43.5-89.8)					
Female	41	56.4	72.7	(52.2-98.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.0	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.3	180.3	(65.8-392.5)
Female	28	22.1	126.8	(84.2-183.2)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.0	nc	(nc-nc)
Male	4	6.6	nc	(nc-nc)	<u>Ovary</u>				
Female	5	5.8	86.8	(28.0-202.7)	Female	0	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	22.3	62.9	(34.3-105.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	7	3.3	212.2	(85.0-437.2)	Female	1	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.6	172.2	(74.1-339.3)
Male	0	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	6	4.9	123.1	(45.0-267.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	60	76.5	78.5	(59.9-101.0)
Female	1	0.5	nc	(nc-nc)	Female	77	71.6	107.5	(84.9-134.4)
<u>Lung and Bronchus</u>									
Male	6	9.7	61.8	(22.6-134.5)					
Female	4	9.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	100.8	(32.5-235.1)	Male	2	3.0	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	6	12.5	47.8	(17.5-104.1)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	5	5.6	89.1	(28.7-207.9)	<u>Ovary</u>				
Female	5	3.6	137.2	(44.2-320.2)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	12	18.7	64.1	(33.1-111.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	46	63.9	72.0	(52.7-96.1)
Female	0	0.3	nc	(nc-nc)	Female	36	42.2	85.3	(59.8-118.1)
<u>Lung and Bronchus</u>									
Male	5	9.1	55.2	(17.8-128.9)					
Female	9	6.1	146.5	(66.8-278.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	3.4	206.3	(82.6-425.0)	Male	1	2.2	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	8	10.7	74.7	(32.1-147.1)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.1	160.1	(51.6-373.6)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	13.0	92.1	(47.5-160.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	38	45.2	84.1	(59.5-115.5)
Female	0	0.3	nc	(nc-nc)	Female	29	35.9	80.8	(54.1-116.0)
<u>Lung and Bronchus</u>									
Male	2	6.3	nc	(nc-nc)					
Female	3	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	49.0	89.8	(65.2-120.5)	Male	26	30.9	84.1	(55.0-123.3)
Female	22	19.7	111.8	(70.0-169.3)	Female	26	25.2	103.2	(67.4-151.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.7	68.7	(25.1-149.6)	Male	5	8.0	62.4	(20.1-145.7)
Female	8	7.8	102.2	(44.0-201.4)	Female	5	7.0	71.3	(23.0-166.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	35	27.2	128.8	(89.7-179.1)
Female	149	180.0	82.8	(70.0-97.2)	Female	26	24.3	106.8	(69.8-156.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.6	91.1	(33.3-198.4)	Male	20	18.4	109.0	(66.5-168.3)
<u>Colon / Rectum</u>					Female	16	9.3	171.9	(98.2-279.1)
Male	33	58.3	56.6	(39.0-79.5)	<u>Ovary</u>				
Female	52	66.9	77.8	(58.1-102.0)	Female	16	17.9	89.4	(51.1-145.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	12.3	129.7	(74.1-210.6)	Male	7	15.6	44.8	(18.0-92.3)
Female	3	4.0	nc	(nc-nc)	Female	10	19.0	52.5	(25.1-96.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.8	nc	(nc-nc)	Male	171	176.4	96.9	(82.9-112.6)
Female	3	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	11.3	80.0	(36.5-151.8)
Male	25	24.9	100.3	(64.9-148.1)	Female	3	7.9	nc	(nc-nc)
Female	14	15.4	91.1	(49.8-152.9)	<u>Testis</u>				
<u>Larynx</u>					Male	8	5.9	134.8	(58.0-265.7)
Male	3	7.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.1	nc	(nc-nc)	Male	8	9.5	83.8	(36.1-165.1)
<u>Leukemia</u>					Female	34	29.6	114.9	(79.5-160.5)
Male	20	17.6	113.9	(69.5-175.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	14.2	49.2	(19.7-101.4)	Female	31	40.0	77.4	(52.6-109.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	13.4	82.1	(40.9-146.9)	Male	590	637.8	92.5	(85.2-100.3)
Female	10	5.1	194.6	(93.2-357.9)	Female	598	655.5	91.2	(84.1-98.8)
<u>Lung and Bronchus</u>									
Male	85	88.2	96.4	(77.0-119.2)					
Female	100	94.0	106.3	(86.5-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	36.4	123.7	(90.2-165.6)	Male	31	25.9	119.6	(81.3-169.8)
Female	21	12.2	171.6	(106.2-262.4)	Female	20	20.3	98.4	(60.1-152.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.8	114.8	(52.4-218.0)	Male	5	6.3	79.0	(25.5-184.4)
Female	8	6.3	126.1	(54.3-248.5)	Female	5	4.5	111.7	(36.0-260.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	18	22.4	80.5	(47.7-127.3)
Female	123	144.1	85.4	(70.9-101.8)	Female	18	16.7	107.8	(63.9-170.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.0	82.7	(26.7-193.1)	Male	18	16.4	109.5	(64.9-173.1)
<u>Colon / Rectum</u>					Female	3	6.9	nc	(nc-nc)
Male	51	46.3	110.2	(82.0-144.9)	<u>Ovary</u>				
Female	38	40.0	94.9	(67.1-130.2)	Female	16	13.6	117.9	(67.4-191.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.3	116.7	(60.3-203.9)	Male	12	12.0	99.8	(51.5-174.3)
Female	3	2.5	nc	(nc-nc)	Female	12	11.4	105.6	(54.5-184.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.6	nc	(nc-nc)	Male	124	153.0	81.0	(67.4-96.6)
Female	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.8	113.7	(54.4-209.0)
Male	29	21.7	133.6	(89.4-191.9)	Female	2	4.5	nc	(nc-nc)
Female	12	11.6	103.6	(53.5-180.9)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.2	145.4	(66.4-276.1)
Male	6	6.1	98.8	(36.1-215.1)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	10	9.2	108.4	(51.9-199.3)
<u>Leukemia</u>					Female	25	28.6	87.5	(56.6-129.2)
Male	23	14.0	164.3	(104.1-246.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	9.8	174.3	(101.5-279.1)	Female	33	33.4	98.7	(67.9-138.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	11.6	94.6	(47.2-169.3)	Male	572	526.4	108.7	(99.9-117.9)
Female	2	3.5	nc	(nc-nc)	Female	485	481.5	100.7	(92.0-110.1)
<u>Lung and Bronchus</u>									
Male	94	69.1	136.1	(110.0-166.6)					
Female	77	65.4	117.8	(92.9-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.7	103.2	(49.4-189.8)	Male	4	6.8	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.9	84.5	(27.2-197.1)
Female	28	33.7	83.1	(55.2-120.1)	Female	7	3.9	178.3	(71.4-367.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	9	12.1	74.4	(34.0-141.3)	<u>Ovary</u>				
Female	5	10.0	49.8	(16.1-116.3)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.7	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	44	40.8	107.9	(78.4-144.8)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.3	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	6	2.7	226.3	(82.6-492.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.3	95.2	(34.8-207.3)
Male	2	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.3	nc	(nc-nc)	Female	9	7.5	120.1	(54.8-228.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.1	nc	(nc-nc)	Male	135	139.3	96.9	(81.3-114.7)
Female	0	0.8	nc	(nc-nc)	Female	113	112.7	100.3	(82.6-120.6)
<u>Lung and Bronchus</u>									
Male	27	18.4	146.6	(96.6-213.3)					
Female	20	15.1	132.5	(80.9-204.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	7	5.1	136.8	(54.8-281.8)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.8	124.6	(45.5-271.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	15.9	113.3	(67.1-179.0)
Female	0	0.1	nc	(nc-nc)	Female	21	16.8	125.1	(77.4-191.3)
<u>Lung and Bronchus</u>									
Male	4	2.0	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.7	134.1	(43.2-312.9)	Male	5	2.8	181.0	(58.3-422.4)
Female	0	1.3	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	16	17.4	92.0	(52.5-149.4)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	5	4.9	102.4	(33.0-238.9)	<u>Ovary</u>				
Female	2	4.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	17	15.4	110.1	(64.1-176.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.4	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	8	3.9	205.3	(88.4-404.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	59	54.9	107.5	(81.8-138.6)
Female	0	0.4	nc	(nc-nc)	Female	48	54.9	87.5	(64.5-116.0)
<u>Lung and Bronchus</u>									
Male	8	7.2	111.5	(48.0-219.7)					
Female	6	6.8	87.8	(32.1-191.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	361	482.4	74.8	(67.3-83.0)	Male	261	341.9	76.3	(67.4-86.2)
Female	131	194.5	67.4	(56.3-79.9)	Female	262	316.7	82.7	(73.0-93.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	83	108.9	76.2	(60.7-94.5)	Male	103	81.0	127.1	(103.8-154.2)
Female	98	98.5	99.5	(80.8-121.2)	Female	88	69.6	126.4	(101.3-155.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	8	14.1	56.6	(24.4-111.5)	Male	293	297.8	98.4	(87.4-110.3)
Female	1763	2016.2	87.4	(83.4-91.6)	Female	214	259.0	82.6	(71.9-94.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	106	91.7	115.6	(94.6-139.8)	Male	211	202.2	104.3	(90.7-119.4)
<u>Colon / Rectum</u>					Female	101	102.6	98.4	(80.2-119.6)
Male	634	596.2	106.3	(98.2-115.0)	<u>Ovary</u>				
Female	639	646.2	98.9	(91.4-106.9)	Female	175	198.3	88.3	(75.7-102.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	99	127.8	77.5	(62.9-94.3)	Male	148	156.6	94.5	(79.9-111.0)
Female	46	39.7	115.9	(84.9-154.7)	Female	200	184.1	108.7	(94.1-124.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	52	64.8	80.3	(59.9-105.3)	Male	1895	1847.7	102.6	(98.0-107.3)
Female	73	53.7	136.0	(106.6-171.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	119	113.6	104.7	(86.8-125.3)
Male	271	271.0	100.0	(88.4-112.6)	Female	100	74.9	133.5	(108.6-162.4)
Female	194	169.8	114.3	(98.8-131.5)	<u>Testis</u>				
<u>Larynx</u>					Male	91	121.6	74.8	(60.2-91.9)
Male	78	74.4	104.9	(82.9-130.9)	<u>Thyroid</u>				
Female	27	23.7	114.1	(75.1-165.9)	Male	121	126.5	95.7	(79.4-114.3)
<u>Leukemia</u>					Female	500	440.0	113.6	(103.9-124.0)
Male	153	191.2	80.0	(67.8-93.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	124	154.2	80.4	(66.9-95.9)	Female	438	454.5	96.4	(87.6-105.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	251	143.5	174.9	(154.0-198.0)	Male	6671	6766.1	98.6	(96.2-101.0)
Female	79	53.8	146.9	(116.3-183.0)	Female	6747	7198.3	93.7	(91.5-96.0)
<u>Lung and Bronchus</u>									
Male	914	884.2	103.4	(96.8-110.3)					
Female	845	985.0	85.8	(80.1-91.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.6	86.6	(54.9-129.9)	Male	27	16.2	166.3	(109.6-242.0)
Female	14	9.9	141.1	(77.1-236.8)	Female	15	12.3	122.4	(68.4-201.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.5	110.9	(35.7-258.8)	Male	2	4.3	nc	(nc-nc)
Female	8	3.9	207.5	(89.3-408.8)	Female	7	3.5	199.6	(80.0-411.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	13	14.3	91.0	(48.4-155.7)
Female	90	91.4	98.5	(79.2-121.1)	Female	10	12.2	81.7	(39.1-150.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	12	9.4	127.0	(65.6-221.9)
<u>Colon / Rectum</u>					Female	5	4.7	106.3	(34.2-248.0)
Male	32	30.7	104.4	(71.4-147.4)	<u>Ovary</u>				
Female	22	32.0	68.7	(43.0-104.0)	Female	14	8.9	156.4	(85.5-262.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.6	106.3	(42.6-219.0)	Male	7	8.4	83.4	(33.4-171.8)
Female	5	2.1	242.5	(78.1-565.9)	Female	11	9.4	116.8	(58.2-208.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	112	93.9	119.2	(98.2-143.4)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.0	100.4	(36.7-218.5)
Male	11	13.1	84.0	(41.9-150.4)	Female	4	3.7	nc	(nc-nc)
Female	7	8.0	87.7	(35.1-180.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	16	14.2	113.0	(64.5-183.5)
Male	13	9.3	139.9	(74.4-239.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	6.9	158.9	(79.2-284.3)	Female	13	20.8	62.5	(33.3-106.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.0	99.4	(39.8-204.8)	Male	378	338.6	111.6	(100.7-123.5)
Female	1	2.6	nc	(nc-nc)	Female	344	330.0	104.2	(93.5-115.9)
<u>Lung and Bronchus</u>									
Male	57	48.0	118.8	(90.0-153.9)					
Female	61	50.6	120.5	(92.2-154.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.9	nc	(nc-nc)	Male	9	3.1	294.3	(134.3-558.7)
Female	1	1.4	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	19	18.1	104.8	(63.1-163.7)	Female	5	2.0	252.9	(81.5-590.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.7	147.9	(59.2-304.7)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	24	18.1	132.5	(84.9-197.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.7	135.8	(43.8-316.9)
Male	1	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	4.1	122.9	(39.6-286.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	54	61.2	88.3	(66.3-115.2)
Female	0	0.4	nc	(nc-nc)	Female	58	58.3	99.5	(75.5-128.6)
<u>Lung and Bronchus</u>									
Male	1	7.8	nc	(nc-nc)					
Female	5	7.4	67.3	(21.7-157.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.3	96.6	(44.1-183.3)	Male	19	6.2	306.0	(184.1-477.8)
Female	0	2.8	nc	(nc-nc)	Female	8	4.3	186.5	(80.3-367.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	5.4	nc	(nc-nc)
Female	40	32.4	123.6	(88.3-168.4)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	8	11.5	69.3	(29.8-136.5)	<u>Ovary</u>				
Female	4	9.1	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.5	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	51	36.3	140.5	(104.6-184.8)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.2	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	5	2.6	193.9	(62.5-452.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	10	5.8	172.5	(82.6-317.3)
Male	8	3.4	235.0	(101.2-463.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	6	7.4	81.2	(29.7-176.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.9	nc	(nc-nc)	Male	135	127.6	105.8	(88.7-125.2)
Female	0	0.8	nc	(nc-nc)	Female	118	107.1	110.1	(91.2-131.9)
<u>Lung and Bronchus</u>									
Male	5	17.3	28.9	(9.3-67.4)					
Female	18	14.9	120.6	(71.4-190.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.1	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	23	18.3	125.6	(79.6-188.4)	Female	0	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.9	nc	(nc-nc)
Male	1	5.4	nc	(nc-nc)	<u>Ovary</u>				
Female	9	5.2	172.4	(78.7-327.3)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	23	16.7	137.6	(87.2-206.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.0	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	59	59.3	99.5	(75.7-128.3)
Female	0	0.4	nc	(nc-nc)	Female	51	60.7	84.1	(62.6-110.5)
<u>Lung and Bronchus</u>									
Male	5	7.7	65.3	(21.1-152.5)					
Female	4	8.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	40.7	118.1	(87.0-156.5)	Male	35	25.7	136.1	(94.8-189.3)
Female	15	16.6	90.3	(50.5-148.9)	Female	42	22.1	189.9	(136.9-256.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.4	149.5	(74.5-267.6)	Male	8	6.6	121.4	(52.3-239.3)
Female	9	6.9	131.2	(59.9-249.0)	Female	9	5.9	151.7	(69.2-288.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	20	22.4	89.1	(54.4-137.7)
Female	163	161.2	101.1	(86.2-117.9)	Female	23	21.0	109.6	(69.5-164.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.0	100.1	(36.6-217.9)	Male	16	15.3	104.4	(59.6-169.6)
<u>Colon / Rectum</u>					Female	6	8.1	73.9	(27.0-160.8)
Male	51	47.7	106.8	(79.5-140.5)	<u>Ovary</u>				
Female	76	54.3	139.9	(110.2-175.1)	Female	20	15.5	129.0	(78.8-199.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.4	134.4	(73.4-225.5)	Male	5	13.0	38.4	(12.4-89.7)
Female	4	3.5	nc	(nc-nc)	Female	14	15.8	88.9	(48.5-149.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.0	nc	(nc-nc)	Male	156	150.4	103.7	(88.1-121.3)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	9.3	172.3	(98.4-279.9)
Male	19	21.1	89.8	(54.1-140.3)	Female	12	6.3	191.0	(98.6-333.7)
Female	13	13.7	95.0	(50.5-162.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.6	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.9	nc	(nc-nc)	Male	4	8.0	nc	(nc-nc)
<u>Leukemia</u>					Female	29	27.2	106.7	(71.5-153.3)
Male	13	14.4	90.1	(47.9-154.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	12.0	75.3	(34.4-142.9)	Female	38	36.2	104.9	(74.2-144.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	11.2	124.8	(68.2-209.4)	Male	592	533.6	110.9	(102.2-120.2)
Female	3	4.4	nc	(nc-nc)	Female	655	571.6	114.6	(106.0-123.7)
<u>Lung and Bronchus</u>									
Male	92	74.6	123.3	(99.4-151.2)					
Female	106	84.1	126.0	(103.2-152.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	21.5	78.9	(46.0-126.4)	Male	22	11.9	184.3	(115.4-279.0)
Female	8	6.5	123.3	(53.1-243.1)	Female	18	7.7	233.4	(138.2-368.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.0	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	10.5	94.8	(45.4-174.4)
Female	59	59.7	98.9	(75.3-127.5)	Female	9	8.0	112.7	(51.4-214.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	11	6.7	163.6	(81.6-292.8)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	19	23.7	80.1	(48.2-125.1)	<u>Ovary</u>				
Female	15	20.9	71.8	(40.2-118.5)	Female	1	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.1	nc	(nc-nc)	Male	7	6.6	105.6	(42.3-217.6)
Female	2	1.4	nc	(nc-nc)	Female	8	6.2	130.0	(56.0-256.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	82	72.0	113.9	(90.6-141.4)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.7	nc	(nc-nc)
Male	8	9.6	83.5	(36.0-164.6)	Female	1	2.4	nc	(nc-nc)
Female	2	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.7	nc	(nc-nc)
Male	4	6.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.3	nc	(nc-nc)	Female	16	14.1	113.6	(64.9-184.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.2	nc	(nc-nc)	Male	246	257.8	95.4	(83.9-108.1)
Female	1	1.7	nc	(nc-nc)	Female	195	214.7	90.8	(78.5-104.5)
<u>Lung and Bronchus</u>									
Male	26	38.1	68.2	(44.5-99.9)					
Female	24	33.2	72.2	(46.2-107.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	24.8	92.9	(58.9-139.4)	Male	19	18.2	104.6	(62.9-163.3)
Female	10	6.9	145.2	(69.5-267.0)	Female	15	11.5	130.9	(73.2-215.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.6	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	13	15.7	83.0	(44.1-141.9)
Female	97	78.9	122.9	(99.7-149.9)	Female	10	9.4	106.5	(51.0-195.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.3	nc	(nc-nc)	Male	8	11.6	68.7	(29.6-135.4)
<u>Colon / Rectum</u>					Female	7	3.8	183.6	(73.5-378.2)
Male	23	31.2	73.7	(46.7-110.6)	<u>Ovary</u>				
Female	32	22.7	140.7	(96.2-198.6)	Female	10	7.5	133.4	(63.9-245.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.1	98.6	(39.5-203.1)	Male	10	8.2	121.7	(58.3-223.8)
Female	4	1.4	nc	(nc-nc)	Female	8	6.4	124.1	(53.4-244.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.9	nc	(nc-nc)	Male	85	104.4	81.4	(65.1-100.7)
Female	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.0	nc	(nc-nc)
Male	15	15.3	97.9	(54.7-161.4)	Female	2	2.6	nc	(nc-nc)
Female	3	6.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.9	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	10	6.7	148.2	(70.9-272.6)
<u>Leukemia</u>					Female	18	16.0	112.9	(66.8-178.4)
Male	9	9.7	92.8	(42.3-176.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	5.6	nc	(nc-nc)	Female	21	17.9	117.5	(72.7-179.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	8.1	136.2	(67.9-243.7)	Male	327	362.9	90.1	(80.6-100.4)
Female	1	1.9	nc	(nc-nc)	Female	316	267.4	118.2	(105.5-132.0)
<u>Lung and Bronchus</u>									
Male	50	47.2	105.9	(78.6-139.6)					
Female	43	36.1	119.2	(86.3-160.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	10	16.0	62.3	(29.8-114.6)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	5	4.9	101.8	(32.8-237.6)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	17.2	81.5	(44.5-136.7)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	48	54.0	88.9	(65.6-117.9)
Female	0	0.4	nc	(nc-nc)	Female	57	54.3	104.9	(79.4-135.9)
<u>Lung and Bronchus</u>									
Male	8	6.8	118.5	(51.0-233.5)					
Female	13	7.4	175.1	(93.1-299.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	80.8	100.3	(79.7-124.7)	Male	43	56.2	76.5	(55.4-103.0)
Female	22	31.1	70.7	(44.3-107.0)	Female	29	48.2	60.2	(40.3-86.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	17.5	74.2	(39.5-126.9)	Male	15	13.8	109.0	(60.9-179.7)
Female	9	15.4	58.5	(26.7-111.1)	Female	15	11.3	133.2	(74.5-219.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.4	nc	(nc-nc)	Male	47	49.1	95.6	(70.3-127.2)
Female	292	337.0	86.6	(77.0-97.2)	Female	57	41.3	138.0	(104.5-178.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	28	13.8	203.4	(135.1-294.0)	Male	42	35.0	120.0	(86.5-162.2)
<u>Colon / Rectum</u>					Female	10	16.5	60.5	(29.0-111.3)
Male	116	100.8	115.1	(95.1-138.0)	<u>Ovary</u>				
Female	129	103.4	124.7	(104.1-148.2)	Female	27	32.2	84.0	(55.3-122.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	34	22.0	154.6	(107.1-216.1)	Male	28	26.5	105.6	(70.1-152.6)
Female	11	6.4	172.2	(85.9-308.2)	Female	36	29.4	122.6	(85.8-169.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	8.4	71.3	(26.0-155.2)	Male	310	319.5	97.0	(86.5-108.4)
Female	8	6.9	115.6	(49.8-227.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	19	19.1	99.4	(59.8-155.2)
Male	54	46.4	116.4	(87.4-151.8)	Female	18	11.8	153.1	(90.7-242.0)
Female	36	27.8	129.6	(90.8-179.4)	<u>Testis</u>				
<u>Larynx</u>					Male	14	14.2	98.3	(53.7-164.9)
Male	20	12.8	155.9	(95.2-240.8)	<u>Thyroid</u>				
Female	4	3.9	nc	(nc-nc)	Male	22	19.8	111.1	(69.6-168.2)
<u>Leukemia</u>					Female	80	64.9	123.3	(97.8-153.5)
Male	27	31.7	85.2	(56.1-124.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	24.7	68.8	(40.0-110.1)	Female	69	76.0	90.8	(70.6-114.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	28	25.0	112.2	(74.6-162.2)	Male	1192	1136.3	104.9	(99.0-111.0)
Female	15	8.7	172.8	(96.6-285.0)	Female	1225	1162.1	105.4	(99.6-111.5)
<u>Lung and Bronchus</u>									
Male	181	150.2	120.5	(103.6-139.4)					
Female	202	160.9	125.5	(108.8-144.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.0	176.5	(70.7-363.7)	Male	3	2.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	15	16.7	89.8	(50.2-148.2)	Female	0	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.9	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	19.7	50.7	(24.3-93.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	4.0	123.7	(39.8-288.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	44	60.7	72.5	(52.7-97.3)
Female	2	0.4	nc	(nc-nc)	Female	50	56.9	87.9	(65.2-115.9)
<u>Lung and Bronchus</u>									
Male	6	7.9	75.7	(27.7-164.9)					
Female	8	8.4	95.8	(41.3-188.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	55	56.5	97.4	(73.4-126.8)	Male	52	37.3	139.2	(104.0-182.6)
Female	15	20.8	72.0	(40.3-118.8)	Female	60	32.0	187.6	(143.2-241.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	10.9	184.2	(112.5-284.5)	Male	8	9.3	86.0	(37.0-169.5)
Female	12	9.9	120.9	(62.4-211.2)	Female	10	7.5	133.8	(64.1-246.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	39	32.4	120.5	(85.7-164.8)
Female	245	213.4	114.8	(100.9-130.1)	Female	29	27.2	106.6	(71.4-153.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	9.0	55.8	(18.0-130.3)	Male	16	22.5	71.1	(40.6-115.5)
<u>Colon / Rectum</u>					Female	8	10.9	73.2	(31.5-144.3)
Male	55	67.5	81.4	(61.3-106.0)	<u>Ovary</u>				
Female	64	68.3	93.7	(72.2-119.7)	Female	22	21.2	103.8	(65.0-157.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	15.0	60.2	(27.5-114.2)	Male	20	18.2	109.9	(67.1-169.8)
Female	6	4.2	143.3	(52.3-312.0)	Female	20	19.6	101.8	(62.2-157.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	5.4	93.3	(30.1-217.7)	Male	220	219.3	100.3	(87.5-114.5)
Female	7	5.0	138.7	(55.6-285.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	13.0	53.7	(21.5-110.6)
Male	28	30.3	92.5	(61.4-133.7)	Female	11	7.9	138.7	(69.2-248.2)
Female	20	18.0	111.4	(68.0-172.0)	<u>Testis</u>				
<u>Larynx</u>					Male	13	9.2	140.9	(74.9-240.9)
Male	5	8.7	57.3	(18.5-133.8)	<u>Thyroid</u>				
Female	0	2.6	nc	(nc-nc)	Male	27	12.3	219.2	(144.4-318.9)
<u>Leukemia</u>					Female	55	42.7	128.9	(97.1-167.7)
Male	36	20.6	175.1	(122.7-242.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	15.9	94.5	(52.8-155.8)	Female	48	50.4	95.3	(70.2-126.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	16.3	nc	(nc-nc)	Male	723	767.7	94.2	(87.4-101.3)
Female	5	5.7	87.8	(28.3-205.0)	Female	797	757.3	105.2	(98.1-112.8)
<u>Lung and Bronchus</u>									
Male	68	104.0	65.4	(50.8-82.9)					
Female	79	105.2	75.1	(59.5-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	11	10.2	107.6	(53.6-192.6)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	12.6	71.7	(32.7-136.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	26	46.8	55.6	(36.3-81.4)
Female	0	0.3	nc	(nc-nc)	Female	28	35.7	78.5	(52.2-113.5)
<u>Lung and Bronchus</u>									
Male	1	6.9	nc	(nc-nc)					
Female	3	5.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	27.5	116.3	(79.6-164.2)	Male	18	18.2	98.9	(58.6-156.4)
Female	11	11.1	99.0	(49.3-177.1)	Female	19	14.9	127.3	(76.6-198.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.3	151.6	(65.3-298.8)	Male	8	4.6	175.0	(75.3-344.8)
Female	1	4.7	nc	(nc-nc)	Female	5	4.0	125.9	(40.6-293.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	15.6	115.2	(68.2-182.1)
Female	108	108.5	99.5	(81.6-120.1)	Female	14	14.1	99.6	(54.4-167.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	7	10.8	64.6	(25.9-133.2)
<u>Colon / Rectum</u>					Female	6	5.5	108.7	(39.7-236.5)
Male	28	32.8	85.4	(56.7-123.4)	<u>Ovary</u>				
Female	33	35.8	92.2	(63.5-129.5)	Female	5	10.5	47.7	(15.4-111.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.3	68.4	(22.0-159.6)	Male	9	8.9	101.4	(46.3-192.5)
Female	3	2.3	nc	(nc-nc)	Female	11	10.5	104.7	(52.2-187.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	103	107.6	95.8	(78.2-116.1)
Female	4	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.3	110.3	(44.2-227.3)
Male	17	15.0	113.5	(66.1-181.7)	Female	6	4.1	144.8	(52.9-315.1)
Female	8	9.3	86.0	(37.0-169.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.9	126.8	(40.9-296.0)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	8	6.0	133.6	(57.5-263.3)
<u>Leukemia</u>					Female	18	18.6	97.0	(57.5-153.4)
Male	14	9.8	142.6	(77.9-239.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	8.1	73.9	(27.0-160.8)	Female	28	24.9	112.7	(74.8-162.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	7.9	126.4	(60.5-232.4)	Male	388	374.2	103.7	(93.6-114.6)
Female	1	2.9	nc	(nc-nc)	Female	386	385.2	100.2	(90.5-110.7)
<u>Lung and Bronchus</u>									
Male	56	51.8	108.0	(81.6-140.3)					
Female	53	57.2	92.6	(69.3-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	84.8	51.9	(37.7-69.6)	Male	53	59.8	88.7	(66.4-116.0)
Female	23	33.4	68.8	(43.6-103.3)	Female	48	54.4	88.3	(65.1-117.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	18.8	90.4	(52.6-144.7)	Male	15	14.0	107.0	(59.9-176.5)
Female	12	16.6	72.5	(37.4-126.6)	Female	9	12.0	75.2	(34.3-142.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.5	nc	(nc-nc)	Male	48	51.9	92.6	(68.2-122.7)
Female	290	344.5	84.2	(74.8-94.5)	Female	21	44.3	47.4	(29.3-72.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	15.5	64.4	(30.9-118.5)	Male	24	34.8	68.9	(44.2-102.6)
<u>Colon / Rectum</u>					Female	14	17.8	78.8	(43.1-132.3)
Male	81	103.8	78.1	(62.0-97.0)	<u>Ovary</u>				
Female	84	110.9	75.7	(60.4-93.8)	Female	22	34.5	63.8	(40.0-96.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	22.2	27.0	(9.8-58.7)	Male	14	27.4	51.1	(27.9-85.8)
Female	4	6.7	nc	(nc-nc)	Female	21	31.5	66.6	(41.2-101.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	12.0	83.4	(39.9-153.4)	Male	270	322.1	83.8	(74.1-94.4)
Female	6	9.3	64.7	(23.6-140.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	19.8	70.6	(38.5-118.4)
Male	31	46.7	66.3	(45.1-94.2)	Female	12	12.9	93.1	(48.0-162.6)
Female	16	28.9	55.3	(31.6-89.9)	<u>Testis</u>				
<u>Larynx</u>					Male	22	23.1	95.1	(59.6-144.0)
Male	9	13.0	69.5	(31.7-131.9)	<u>Thyroid</u>				
Female	1	4.1	nc	(nc-nc)	Male	28	22.2	126.3	(83.9-182.6)
<u>Leukemia</u>					Female	80	75.0	106.7	(84.6-132.8)
Male	19	33.1	57.4	(34.5-89.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	26.0	103.7	(68.4-151.0)	Female	74	80.0	92.5	(72.6-116.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	24.7	101.3	(65.5-149.5)	Male	911	1182.0	77.1	(72.1-82.2)
Female	13	9.2	141.0	(75.0-241.1)	Female	968	1232.9	78.5	(73.6-83.6)
<u>Lung and Bronchus</u>									
Male	107	154.3	69.3	(56.8-83.8)					
Female	106	167.7	63.2	(51.8-76.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	26.9	55.7	(31.2-91.9)	Male	17	16.8	101.1	(58.8-161.8)
Female	10	11.2	89.5	(42.8-164.5)	Female	7	13.9	50.2	(20.1-103.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.8	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	8	4.0	202.3	(87.1-398.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	8	14.8	54.1	(23.3-106.6)
Female	95	101.0	94.1	(76.1-115.0)	Female	20	13.7	146.0	(89.2-225.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	5	10.1	49.7	(16.0-116.0)
<u>Colon / Rectum</u>					Female	10	5.3	189.2	(90.6-348.1)
Male	41	32.1	127.9	(91.8-173.5)	<u>Ovary</u>				
Female	32	37.6	85.1	(58.2-120.2)	Female	6	10.1	59.6	(21.8-129.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.8	103.2	(41.4-212.7)	Male	12	8.6	139.7	(72.1-244.0)
Female	0	2.3	nc	(nc-nc)	Female	8	10.8	74.2	(31.9-146.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.9	nc	(nc-nc)	Male	91	97.3	93.5	(75.3-114.8)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.2	81.3	(26.2-189.7)
Male	9	13.5	66.7	(30.4-126.5)	Female	2	4.5	nc	(nc-nc)
Female	11	8.6	127.7	(63.7-228.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.0	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Leukemia</u>					Female	19	16.4	116.1	(69.9-181.4)
Male	10	9.8	102.5	(49.1-188.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.1	61.6	(19.9-143.8)	Female	21	22.7	92.6	(57.3-141.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.3	81.7	(29.8-177.7)	Male	331	349.3	94.8	(84.8-105.5)
Female	0	2.9	nc	(nc-nc)	Female	353	368.5	95.8	(86.1-106.3)
<u>Lung and Bronchus</u>									
Male	46	48.0	95.9	(70.2-127.9)					
Female	59	52.9	111.5	(84.9-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;